(Total Views: 732)
Posted On: 05/26/2024 2:17:54 PM
Post# of 148870
Re: HHIGambler #143699
Why leronlimab won't be shelved:
Let's get down to the root of its operation. What is a Cytokine? It is a protein that the white blood cells comprising our immune system use to communicate with themselves, so they know when it is a time of peace or a time of war. So, they know if there are invaders or if there are no invaders. These leucocytes use cytokines to communicate between themselves, whether or not, a pathologic process is currently taking place in the body, and they communicate what actions to take to bring the body back into a state of health.
Many times, though, the road to get healthy is through a road of worsening inflammatory heat, but the immune system knows the path to take to bring the body back to health and it will always get there provided its cytokine signaling remains healthy.
What cytokine does Leronlimab control? Leronlimab binds to CCR5 which in fact has a multitude of different uses depending on context. CCR5 receptors are used in many disease states, but CytoDyn is developing Leronlimab to bind with CCR5 focusing on HIV, mTNBC, mCRC, NASH, Long Haulers, previously Covid, MSS Tumors, GlioBlastoma Multiforme, Alzheimers and many others such as Graft vs Host disease, but this is only the beginning.
The truth is that because CCR5 operates at the heart of communication signaling of the immune system, it is involved in a tremendous number of disease processes. Just about all disease processes require the immune system to overcome the pathology. Therefore, CCR5 is involved in just about all disease processes. And because Leronlimab binds so efficiently to CCR5 and has a significantly long half-life of about 2 weeks, it has impressive effects on mitigating a whole host of disease processes while it remains bound to CCR5. After a week or two, if its effects begin to wane, another sub-q injection of leronlimab may be given, extending its benefits. There are no ASEs.
CytoDyn is at early stages in the development of Leronlimab. It is a small company, struggling to stay alive in the development of this monoclonal antibody. However, because of the effectiveness of this molecule, CytoDyn manages to remain alive.
This molecule is capable of too much for it not to become a part of humanity. There is too much good that this molecule can do for it not to become a part of human history. It will be proven effective for a myriad of pathologies and disease processes across the spectrum of disease from infectious disease, to cancer, to gastrointestinal disease to neurologic disease to pulmonary disease to vascular. Across the gamut, it will have a role. And what role will that be?
Leronlimab will be used as an adjuvant. It will be combined with current medications to augment their mechanism of action. Because it works at the heart of the immune system, it will provide the proper mileu for current medications to work better.
Leronlimab is being studied by potential suitors, by companies who require something to boost their current solutions. With all the technology and recent research papers, they are noticing that the answer lies in the microenvironment of intra-cellular communication, in the world of interleukins, chemokines and cytokines. They are understanding, that by controlling cellular communication, they can control the body's capacity to eradicate disease and restore health. They are understanding that the way to return to health is via the immune system because in fact, when the body is unhealthy, there exists something in the immune system which has gone awry and that something is usually due to faulty communication.
Faulty communication results by the hijacking of the CCR5 receptor by a ligand called RANTES or CCL5. When too many RANTES clogs up the CCR5 receptors, the immune system begins to fail. For instance, Tumors begin to exude RANTES to clog up the CCR5 receptors on the T regulatory cells to make them think that the tumor is self and not foreign. That causes the T regulatory cells to communicate with the Natural Killer Cells and to instruct them NOT to kill the tumor cell. There are many deceitful mechanisms that use RANTES to put the immune system in a trance like state and allow disease processes to persist.
But when Leronlimab is introduced, it displaces RANTES from its bind with CCR5 and leronlimab is bound by CCR5 instead. Restoration of proper intracellular chemical communication is restored, and the disease process begins to be defeated. The objective of the immune system is to restore health and it accomplishes that with healthy intracellular communication.
The fact is though, that leronlimab is so versatile and so useful, that the eventual outcome for CytoDyn will be successful. It is just about guaranteed because the molecule is that good and that necessary to an improved human civilization. For becoming more civilized with less harmful drugs and with more effective drugs leading to health and not perpetual disease. We are at the beginning of the football game, but we already know the winner.
Go ahead rodolfo, I already know it's coming.
Let's get down to the root of its operation. What is a Cytokine? It is a protein that the white blood cells comprising our immune system use to communicate with themselves, so they know when it is a time of peace or a time of war. So, they know if there are invaders or if there are no invaders. These leucocytes use cytokines to communicate between themselves, whether or not, a pathologic process is currently taking place in the body, and they communicate what actions to take to bring the body back into a state of health.
Many times, though, the road to get healthy is through a road of worsening inflammatory heat, but the immune system knows the path to take to bring the body back to health and it will always get there provided its cytokine signaling remains healthy.
What cytokine does Leronlimab control? Leronlimab binds to CCR5 which in fact has a multitude of different uses depending on context. CCR5 receptors are used in many disease states, but CytoDyn is developing Leronlimab to bind with CCR5 focusing on HIV, mTNBC, mCRC, NASH, Long Haulers, previously Covid, MSS Tumors, GlioBlastoma Multiforme, Alzheimers and many others such as Graft vs Host disease, but this is only the beginning.
The truth is that because CCR5 operates at the heart of communication signaling of the immune system, it is involved in a tremendous number of disease processes. Just about all disease processes require the immune system to overcome the pathology. Therefore, CCR5 is involved in just about all disease processes. And because Leronlimab binds so efficiently to CCR5 and has a significantly long half-life of about 2 weeks, it has impressive effects on mitigating a whole host of disease processes while it remains bound to CCR5. After a week or two, if its effects begin to wane, another sub-q injection of leronlimab may be given, extending its benefits. There are no ASEs.
CytoDyn is at early stages in the development of Leronlimab. It is a small company, struggling to stay alive in the development of this monoclonal antibody. However, because of the effectiveness of this molecule, CytoDyn manages to remain alive.
This molecule is capable of too much for it not to become a part of humanity. There is too much good that this molecule can do for it not to become a part of human history. It will be proven effective for a myriad of pathologies and disease processes across the spectrum of disease from infectious disease, to cancer, to gastrointestinal disease to neurologic disease to pulmonary disease to vascular. Across the gamut, it will have a role. And what role will that be?
Leronlimab will be used as an adjuvant. It will be combined with current medications to augment their mechanism of action. Because it works at the heart of the immune system, it will provide the proper mileu for current medications to work better.
Leronlimab is being studied by potential suitors, by companies who require something to boost their current solutions. With all the technology and recent research papers, they are noticing that the answer lies in the microenvironment of intra-cellular communication, in the world of interleukins, chemokines and cytokines. They are understanding, that by controlling cellular communication, they can control the body's capacity to eradicate disease and restore health. They are understanding that the way to return to health is via the immune system because in fact, when the body is unhealthy, there exists something in the immune system which has gone awry and that something is usually due to faulty communication.
Faulty communication results by the hijacking of the CCR5 receptor by a ligand called RANTES or CCL5. When too many RANTES clogs up the CCR5 receptors, the immune system begins to fail. For instance, Tumors begin to exude RANTES to clog up the CCR5 receptors on the T regulatory cells to make them think that the tumor is self and not foreign. That causes the T regulatory cells to communicate with the Natural Killer Cells and to instruct them NOT to kill the tumor cell. There are many deceitful mechanisms that use RANTES to put the immune system in a trance like state and allow disease processes to persist.
But when Leronlimab is introduced, it displaces RANTES from its bind with CCR5 and leronlimab is bound by CCR5 instead. Restoration of proper intracellular chemical communication is restored, and the disease process begins to be defeated. The objective of the immune system is to restore health and it accomplishes that with healthy intracellular communication.
The fact is though, that leronlimab is so versatile and so useful, that the eventual outcome for CytoDyn will be successful. It is just about guaranteed because the molecule is that good and that necessary to an improved human civilization. For becoming more civilized with less harmful drugs and with more effective drugs leading to health and not perpetual disease. We are at the beginning of the football game, but we already know the winner.
Go ahead rodolfo, I already know it's coming.
(15)
(0)Scroll down for more posts ▼
